IL6 and neoplasm: This is the first evidence, to the best of our knowledge, that an intrinsic immunosuppressive pathway (IL-6/STAT3) can directly affect tumor antigenicity leading to changes in the T-cell lymphocyte repertoire and restrict antigen dependent tumor immunity.